The oligonucleotide therapy market is booming, projected to reach $87.8B by 2033, driven by advancements in ASO, siRNA, and mRNA technologies for neuromuscular diseases, hATTR, and COVID-19. Explore market trends, key players (e.g., Ionis, Alnylam, Biogen), and regional insights in this comprehensive analysis.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.
